BBIO Q4 2021 Earnings — BridgeBio Pharma, Inc. Revenue & Financial Results | Market Cap Arena

BBIOBridgeBio Pharma, Inc.

$14B

Q4 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$13M+10462.3% YoY

Gross Profit

$11M88.0% margin

Operating Income

-$166M-1285.2% margin

Net Income

-$147M-1142.1% margin

EPS (Diluted)

$-1.01

QoQ Revenue Growth

+449.7%

Cash Flow

Operating Cash Flow

-$134M

Free Cash Flow

-$136M

Stock-Based Comp.

$20M

Balance Sheet

Total Assets

$1.0B

Total Liabilities

$1.9B

Stockholders' Equity

-$870M

Cash & Equivalents

$394M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$13M	$122,000	+10462.3%
Gross Profit	$11M	$122,000	+9191.0%
Operating Income	-$166M	-$127M	-29.9%
Net Income	-$147M	-$120M	-22.7%

Revenue Segments

License

$64M97%

Product

$2M3%